As the industry continues to innovate across novel small- and large-molecule therapies, including ribonucleic acid (RNA)-targeted small molecules, cell and gene therapies, and messenger ribonucleic acid (mRNA) therapies, pharma sponsors increasingly rely on partners for technology access, database generation and analysis, and preclinical and clinical research.

These disruptions continue to drive industry transformation through a convergence model in which multiple vendors support different stages of drug discovery and development. The ecosystem is expanding through simultaneous reliance on pure-play technology vendors, AI platform providers, academia, universities, research centers, and outsourcing vendors such as contract research organizations (CROs) that integrate AI algorithms into preclinical and clinical research portfolios.

• How have AI companies evolved beyond pure-play platform-as-a-service models into AI-powered therapeutics providers?
• Which growth avenues can help you build proprietary asset pipelines that directly compete with global biopharma companies while continuing to partner with biopharma sponsors to develop novel therapies?
• In what ways will growing interest in precision medicine drive partnerships with organ-on-chip technology providers and synthetic biology companies and further expand the ecosystem?